Calcipotriene
A synthetic analogue of the active form of vitamin D used topically to treat mild to moderate plaque psoriasis. It works by slowing the rapid skin cell growth and normalizing the skin cell lifecycle associated with psoriasis. It is well tolerated on most body areas but should be avoided on the face due to the risk of irritation.
Peso molecular
412,6000 g/mol
LogP
4,30
TPSA
60,70 Ų
Regla de cinco de Lipinski
Cumple
Áreas terapéuticas
Mecanismo de acción
Serves as an essential micronutrient cofactor in various enzymatic reactions and metabolic processes. Supplementation corrects deficiency states and supports normal physiological function.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Serves as an essential micronutrient cofactor in various enzymatic reactions and metabolic processes. Supplementation corrects deficiency states and supports normal physiological function.
Estructura 2D
Cite this structure
Embed this structure
SMILES
C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/[C@@H](O)C4CC4)CC[C@@H]23)C[C@@H](O)C[C@@H]1O
InChI
InChI=1S/C27H40O3/c1-17(6-13-25(29)20-8-9-20)23-11-12-24-19(5-4-14-27(23,24)3)7-10-21-15-22(28)16-26(30)18(21)2/h6-7,10,13,17,20,22-26,28-30H,2,4-5,8-9,11-12,14-16H2,1,3H3/b13-6+,19-7+,21-10-/t17-,22-,23-,24+,25-,26+,27-/m1/s1
Molecular Formula
C27H40O3
HBD / HBA
3 / 3
Enlaces Rotables
5
Átomos Pesados
30
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
A synthetic analogue of the active form of vitamin D used topically to treat mild to moderate plaque psoriasis. It works by slowing the rapid skin cell growth and normalizing the skin cell lifecycle associated with psoriasis. It is well tolerated on most body areas but should be avoided on the face due to the risk of irritation.
Serves as an essential micronutrient cofactor in various enzymatic reactions and metabolic processes. Supplementation corrects deficiency states and supports normal physiological function.
Yes, Calcipotriene is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200666. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5288783. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="calcipotriene"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/calcipotriene/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/calcipotriene/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/calcipotriene/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="calcipotriene"></drugfyi-drug>